Aleta’s lead program, ALETA-001, is a first-in-class CTE currently in a Cancer Research UK-funded phase 1/2 trial in advanced B-cell lymphoma patients who have received CD19-targeting CAR T-cell ...

“At one point in time, you probably don’t have B cells in the body,” he said. “The only cell surviving that attack is actually the plasma cell, because the plasma cell has no CD19 on its ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most ...

Impressive results have been achieved by adoptively transferring T-cells expressing CD19-specific CARs with binding domains from murine mAbs to treat B-cell malignancies. T-cell mediated immune ...

Blinatumomab (Blincyto, Amgen) is indicated for 'the treatment of adult patients with Philadelphia chromosome negative CD19-positive B-cell precursor leukaemia ALL in the consolidation phase'. The ...

Immunofluorescence staining for apoptotic (TUNEL) and B cells (CD19) in the spleens of mice at 14 days after the first ...

Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...